Global trial tests drug to shrink debilitating tumors

NCT ID NCT04924608

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This global Phase 3 study is testing whether the drug selumetinib is effective and safe for adults with neurofibromatosis type 1 (NF1) who have painful, inoperable tumors called plexiform neurofibromas. The main goal is to see if the drug can shrink these tumors and reduce chronic pain compared to a placebo. The study involves 145 participants and is designed to provide clear evidence for potential treatment approval.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Gainesville, Florida, 32610, United States
Research Site

Rockville, Maryland, 20852, United States
Research Site

St Louis, Missouri, 63156, United States
Research Site

Commack, New York, 11725, United States
Research Site

Melbourne, 3000, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Porto Alegre, 90035-903, Brazil
Research Site

Ribeirão Preto, 14051-140, Brazil
Research Site

São Paulo, 045202-001, Brazil
Research Site

Toronto, Ontario, M5G 2C4, Canada
Research Site

Montreal, Quebec, H4A 3J1, Canada
Research Site

Beijing, 100070, China
Research Site

Beijing, 100730, China
Research Site

Guangzhou, 510060, China
Research Site

Shenyang, 110001, China
Research Site

Créteil, 94000, France
Research Site

Lyon, 69008, France
Research Site

Toulouse, 31059, France
Research Site

Hamburg, 20246, Germany
Research Site

Tübingen, 72076, Germany
Research Site

Würzburg, 97080, Germany
Research Site

Milan, 20133, Italy
Research Site

Naples, 80131, Italy
Research Site

Roma, 00165, Italy
Research Site

Minatoku, 105-8471, Japan
Research Site

Nagoya, 466-8560, Japan
Research Site

Shinjuku-ku, 160-8582, Japan
Research Site

Bydgoszcz, 85-094, Poland
Research Site

Moscow, 115522, Russia
Research Site

Moscow, 125412, Russia
Research Site

Badalona, 08916, Spain
Research Site

Madrid, 28041, Spain
Research Site

London, SE1 9RT, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom

Conditions

Explore the condition pages connected to this study.

NEUROFIBROMATOSIS 1 PLEXIFORM NEUROFIBROMA (PN)